Jonathan Zalevsky, Ph.D. - Publications

Affiliations: 
2002 University of California, San Francisco, San Francisco, CA 
Area:
Biochemistry, Cell Biology

33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Diab A, Tykodi SS, Daniels GA, Maio M, Curti BD, Lewis KD, Jang S, Kalinka E, Puzanov I, Spira AI, Cho DC, Guan S, Puente E, Nguyen T, Hoch U, ... ... Zalevsky J, et al. Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2100675. PMID 34255535 DOI: 10.1200/JCO.21.00675  0.01
2021 Diab A, Tykodi SS, Daniels GA, Maio M, Curti BD, Lewis KD, Jang S, Kalinka E, Puzanov I, Spira AI, Cho DC, Guan S, Puente E, Nguyen T, Hoch U, ... ... Zalevsky J, et al. Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2100675. PMID 34255535 DOI: 10.1200/JCO.21.00675  0.01
2021 Shah N, Perales MA, Turtle CJ, Cairo MS, Cowan AJ, Saeed H, Budde LE, Tan A, Lee Z, Kai K, Marcondes MQ, Zalevsky J, Tagliaferri MA, Patel KK. Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies. Future Oncology (London, England). PMID 34154392 DOI: 10.2217/fon-2021-0576  0.01
2021 Dixit N, Fanton C, Langowski JL, Kirksey Y, Kirk P, Chang T, Cetz J, Dixit V, Kim G, Kuo P, Maiti M, Tang Y, VanderVeen LA, Zhang P, Lee M, ... ... Zalevsky J, et al. NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. Journal of Translational Autoimmunity. 4: 100103. PMID 34041473 DOI: 10.1016/j.jtauto.2021.100103  0.01
2021 Miyazaki T, Maiti M, Hennessy M, Chang T, Kuo P, Addepalli M, Obalapur P, Sheibani S, Wilczek J, Pena R, Quach P, Cetz J, Moffett A, Tang Y, Kirk P, ... ... Zalevsky J, et al. NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy. Journal For Immunotherapy of Cancer. 9. PMID 34001523 DOI: 10.1136/jitc-2020-002024  0.01
2020 Veatch JR, Singhi N, Jesernig B, Paulson KG, Zalevsky J, Iaccucci E, Tykodi SS, Riddell SR. Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab. Journal For Immunotherapy of Cancer. 8. PMID 33298619 DOI: 10.1136/jitc-2020-001591  0.01
2020 Overwijk WW, Tagliaferri MA, Zalevsky J. Engineering IL-2 to Give New Life to T Cell Immunotherapy. Annual Review of Medicine. PMID 33158368 DOI: 10.1146/annurev-med-073118-011031  0.04
2020 Hennessy M, Wahba A, Felix K, Cabrera M, Segura MG, Kundra V, Ravoori MK, Stewart J, Kleinerman ES, Jensen VB, Gopalakrishnan V, Pena R, Quach P, Kim G, Kivimäe S, ... ... Zalevsky J, et al. Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma. International Journal of Cancer. PMID 33152115 DOI: 10.1002/ijc.33382  0.01
2020 Diab A, Tannir NM, Bentebibel SE, Hwu P, Papadimitrakopoulou V, Haymaker C, Kluger HM, Gettinger SN, Sznol M, Tykodi SS, Curti BD, Tagliaferri MA, Zalevsky J, Hannah AL, Hoch U, et al. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). Cancer Discovery. PMID 32439653 DOI: 10.1158/2159-8290.CD-19-1510  0.01
2020 Kopruszinski CM, Swiokla J, Lee YS, Navratilova E, VanderVeen L, Yang M, Liu Y, Miyazaki T, Schmidt WK, Zalevsky J, Porreca F. Preclinical Assessment of the Analgesic Pharmacology of NKTR-181 in Rodents. Cellular and Molecular Neurobiology. PMID 32107752 DOI: 10.1007/S10571-020-00816-3  0.01
2020 Sharma M, Khong H, Fa'ak F, Bentebibel SE, Janssen LME, Chesson BC, Creasy CA, Forget MA, Kahn LMS, Pazdrak B, Karki B, Hailemichael Y, Singh M, Vianden C, Vennam S, ... ... Zalevsky J, et al. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nature Communications. 11: 661. PMID 32005826 DOI: 10.1038/S41467-020-14471-1  0.01
2020 Parisi G, Saco JD, Salazar FB, Tsoi J, Krystofinski P, Puig-Saus C, Zhang R, Zhou J, Cheung-Lau GC, Garcia AJ, Grasso CS, Tavaré R, Hu-Lieskovan S, Mackay S, Zalevsky J, et al. Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. Nature Communications. 11: 660. PMID 32005809 DOI: 10.1038/S41467-019-12901-3  0.01
2019 Ge X, Henningfield JE, Siddhanti S, Jobes J, Lu L, Xie S, Ziola M, Kelsh D, Vince B, Di Fonzo CJ, Tagliaferri M, Zalevsky J, Doberstein SK, Hoch U, Eldon MA. Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover Study. Pain Medicine (Malden, Mass.). PMID 31553457 DOI: 10.1093/Pm/Pnz232  0.04
2019 Korver W, Carsillo M, Yuan J, Idamakanti N, Wagoner M, Shi P, Xia CQ, Smithson G, McLean L, Zalevsky J, Fedyk ER. A reduction in B, T, and NK cells expressing CD38 by TAK-079 inhibits the induction and progression of collagen-induced arthritis in cynomolgus monkeys. The Journal of Pharmacology and Experimental Therapeutics. PMID 31085699 DOI: 10.1124/jpet.119.256602  0.01
2019 Bentebibel SE, Hurwitz ME, Bernatchez C, Haymaker C, Hudgens CW, Kluger HM, Tetzlaff MT, Tagliaferri MA, Zalevsky J, Hoch U, Fanton C, Aung S, Hwu P, Curti BD, Tannir NM, et al. A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL-2-Receptor Beta/Gamma (βγ)-Biased Cytokine, in Patients With Advanced or Metastatic Solid Tumors. Cancer Discovery. PMID 30988166 DOI: 10.1158/2159-8290.CD-18-1495  0.01
2017 Miyazaki T, Choi IY, Rubas W, Anand NK, Ali C, Evans J, Gursahani H, Hennessy M, Kim G, McWeeney D, Pfeiffer J, Quach P, Gauvin D, Riley TA, Riggs JA, ... ... Zalevsky J, et al. NKTR-181: A Novel Mu-Opioid Analgesic with Inherently Low Abuse Potential. The Journal of Pharmacology and Experimental Therapeutics. PMID 28778859 DOI: 10.1124/jpet.117.243030  0.01
2017 Charych D, Khalili S, Dixit V, Kirk P, Chang T, Langowski J, Rubas W, Doberstein SK, Eldon M, Hoch U, Zalevsky J. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. Plos One. 12: e0179431. PMID 28678791 DOI: 10.1371/journal.pone.0179431  0.04
2016 Lam B, Arikawa Y, Cramlett J, Dong Q, de Jong R, Feher V, Grimshaw CE, Farrell PJ, Hoffman ID, Jennings A, Jones B, Matuszkiewicz J, Miura J, Miyake H, Natala SR, ... ... Zalevsky J, et al. Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK). Bioorganic & Medicinal Chemistry Letters. PMID 27839918 DOI: 10.1016/J.Bmcl.2016.10.087  0.01
2012 Chan WK, Kung Sutherland M, Li Y, Zalevsky J, Schell S, Leung W. Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6296-305. PMID 23014531 DOI: 10.1158/1078-0432.CCR-12-0668  1
2011 Horton HM, Chu SY, Ortiz EC, Pong E, Cemerski S, Leung IW, Jacob N, Zalevsky J, Desjarlais JR, Stohl W, Szymkowski DE. Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. Journal of Immunology (Baltimore, Md. : 1950). 186: 4223-33. PMID 21357255 DOI: 10.4049/jimmunol.1003412  1
2010 Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. Enhanced antibody half-life improves in vivo activity. Nature Biotechnology. 28: 157-9. PMID 20081867 DOI: 10.1038/Nbt.1601  1
2010 Bernett MJ, Karki S, Moore GL, Leung IW, Chen H, Pong E, Nguyen DH, Jacinto J, Zalevsky J, Muchhal US, Desjarlais JR, Lazar GA. Engineering fully human monoclonal antibodies from murine variable regions. Journal of Molecular Biology. 396: 1474-90. PMID 20045416 DOI: 10.1016/j.jmb.2009.12.046  1
2009 Zalevsky J, Leung IW, Karki S, Chu SY, Zhukovsky EA, Desjarlais JR, Carmichael DF, Lawrence CE. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood. 113: 3735-43. PMID 19109559 DOI: 10.1182/blood-2008-10-182048  1
2007 Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, O'Brien C, Eivazi A, Kung J, Nguyen DH, Doberstein SK, Erard F, Ryffel B, Szymkowski DE. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. Journal of Immunology (Baltimore, Md. : 1950). 179: 1872-83. PMID 17641054 DOI: 10.4049/Jimmunol.179.3.1872  1
2006 Oikonomou N, Harokopos V, Zalevsky J, Valavanis C, Kotanidou A, Szymkowski DE, Kollias G, Aidinis V. Soluble TNF mediates the transition from pulmonary inflammation to fibrosis. Plos One. 1: e108. PMID 17205112 DOI: 10.1371/journal.pone.0000108  1
2006 Rutschmann S, Hoebe K, Zalevsky J, Du X, Mann N, Dahiyat BI, Steed P, Beutler B. PanR1, a dominant negative missense allele of the gene encoding TNF-alpha (Tnf), does not impair lymphoid development. Journal of Immunology (Baltimore, Md. : 1950). 176: 7525-32. PMID 16751399 DOI: 10.4049/Jimmunol.176.12.7525  1
2005 Nguyen MT, Satoh H, Favelyukis S, Babendure JL, Imamura T, Sbodio JI, Zalevsky J, Dahiyat BI, Chi NW, Olefsky JM. JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. The Journal of Biological Chemistry. 280: 35361-71. PMID 16085647 DOI: 10.1074/Jbc.M504611200  1
2003 Steed PM, Tansey MG, Zalevsky J, Zhukovsky EA, Desjarlais JR, Szymkowski DE, Abbott C, Carmichael D, Chan C, Cherry L, Cheung P, Chirino AJ, Chung HH, Doberstein SK, Eivazi A, et al. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science (New York, N.Y.). 301: 1895-8. PMID 14512626 DOI: 10.1126/Science.1081297  1
2001 Zalevsky J, Lempert L, Kranitz H, Mullins RD. Different WASP family proteins stimulate different Arp2/3 complex-dependent actin-nucleating activities. Current Biology : Cb. 11: 1903-13. PMID 11747816 DOI: 10.1016/S0960-9822(01)00603-0  1
2001 Zalevsky J, Grigorova I, Mullins RD. Activation of the Arp2/3 complex by the Listeria acta protein. Acta binds two actin monomers and three subunits of the Arp2/3 complex. The Journal of Biological Chemistry. 276: 3468-75. PMID 11029465 DOI: 10.1074/Jbc.M006407200  1
2000 Dernburg AF, Zalevsky J, Colaiácovo MP, Villeneuve AM. Transgene-mediated cosuppression in the C. elegans germ line Genes and Development. 14: 1578-1583. PMID 10887151  1
2000 DeFea KA, Zalevsky J, Thoma MS, Déry O, Mullins RD, Bunnett NW. beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. The Journal of Cell Biology. 148: 1267-81. PMID 10725339 DOI: 10.1083/Jcb.148.6.1267  1
1999 Zalevsky J, MacQueen AJ, Duffy JB, Kemphues KJ, Villeneuve AM. Crossing over during Caenorhabditis elegans meiosis requires a conserved MutS-based pathway that is partially dispensable in budding yeast Genetics. 153: 1271-1283. PMID 10545458  1
Show low-probability matches.